Specific inhibition of the nuclear exporter exportin-1 attenuates kidney cancer growth.

PURPOSE:Despite the advent of FDA-approved therapeutics to a limited number of available targets (kinases and mTOR), PFS of kidney cancer (RCC) has been extended only one to two years due to the development of drug resistance. Here, we evaluate a novel therapeutic for RCC which targets the exportin-...

Full description

Bibliographic Details
Main Authors: Hiromi I Wettersten, Yosef Landesman, Sharon Friedlander, Sharon Shacham, Michael Kauffman, Robert H Weiss
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2014-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4252068?pdf=render

Similar Items